The following was submitted to the FDA in support of the development of additional treatments for men with advanced prostate cancer, including Provenge.

The advocates of “Raise a Voice”, a grass roots initiative for advanced prostate cancer, would like to express our appreciation for the opportunity to present comments at the Cellular, Tissue and Gene Therapies Advisory Committee meeting on March 29, 2007.

We respect and appreciate the importance and difficulty of the FDA’s current process towards decision on approval of Provenge (sipuleucel-T).

Given the following points, we would like to reaffirm our position on the need for additional effective treatments with fewer side effects for advanced prostate cancer.

* The very favorable risk-benefit ratio of Provenge
* The survival data discussed at March 29th meeting
* The necessity for additional effective treatments for advanced and hormone-refractory prostate cancer based on the current US death rate of approximately 27,000 men a year